Venous / arterial thrombosis

What Is Venous and Arterial Thrombosis?

Venous and arterial thrombosis refers to the formation of abnormal blood clots within veins or arteries, and while both share the common outcome of an obstructive clot, the underlying tendency toward clot formation, called thrombophilia, can arise from distinct inherited genetic causes.

The most clearly defined inherited thrombophilias include the factor V Leiden variant and prothrombin gene variant, along with deficiencies in three natural anticlotting proteins, protein C, protein S, and antithrombin, with deficiencies in these three proteins occurring roughly ten times less frequently than factor V Leiden overall.¹

Genetic thrombophilia testing has taken on particular relevance in cancer patients, since specific inherited genetic variants have been shown to meaningfully raise venous thromboembolism risk among people already facing elevated clotting risk from their underlying malignancy.²

Germline mutations, such as factor V Leiden and prothrombin G20210A, are associated with a two to two and a half fold increased venous thromboembolism risk in patients with cancer.
National Center for Biotechnology Information

Symptoms

Venous thromboembolism most commonly affects the legs, though upper extremity, cerebral, and superficial venous thrombosis can also occur, producing symptoms specific to the affected location.¹

Arterial thrombosis produces distinctly different symptoms depending on which artery becomes blocked, potentially triggering a stroke, heart attack, or reduced blood flow to affected tissue, generally with a more sudden onset than venous clots.

Cancer patients face a particularly elevated risk of developing thrombosis, and specific molecular characteristics of certain tumors have been linked to differing degrees of clotting risk, adding an additional layer of complexity to symptom recognition in this population.²

Causes

Inherited deficiencies affecting the body’s natural anticoagulant proteins, protein C, protein S, and antithrombin, represent well established, though comparatively uncommon, causes of thrombophilia, together affecting less than one to two percent of the general population.¹

Beyond inherited genetic thrombophilia, tumor specific genetic mutations have increasingly been recognized as independent contributors to clotting risk in cancer patients, with certain mutations raising risk in some cancer types while, notably, certain other mutations appear to lower thrombosis risk in specific cancers such as gliomas.²

This growing understanding of how both inherited and tumor specific genetic factors influence clotting risk has led researchers to explore whether incorporating this genetic information into existing risk prediction tools might improve their overall accuracy.²

Risk Factors

A personal or family history of blood clots, particularly at a young age or without an obvious triggering event, often prompts consideration of underlying inherited thrombophilia testing.³

Cancer diagnosis itself represents one of the most significant acquired risk factors for thrombosis, and this risk appears to be further modified by both inherited genetic thrombophilia and tumor specific genetic characteristics.²

Testing approaches differ depending on the specific thrombophilia being evaluated, with protein C, protein S, and antithrombin deficiencies typically identified through blood based functional assays, while certain other genetic variants can only be reliably detected through direct genetic testing.¹

Complications

Cancer associated thrombosis represents a particularly serious complication for oncology patients, contributing meaningfully to illness and, in some cases, mortality independent of the underlying cancer itself.²

Research incorporating both inherited genetic thrombophilia markers and tumor specific mutation data has shown improved ability to predict which cancer patients face the highest clotting risk, compared to using standard clinical risk scoring tools alone.²

Because thrombophilia testing carries meaningful implications for treatment decisions and family counseling, professional hematology societies have developed specific guidelines to help clinicians determine which patients are most likely to benefit from formal testing.³

Treatment

Current treatment guidelines recommend either low molecular weight heparin or direct oral anticoagulants as first line options for cancer associated venous thromboembolism, representing a meaningful evolution from older treatment approaches.⁴

Direct oral anticoagulants have demonstrated meaningfully lower rates of clot recurrence compared to low molecular weight heparin in randomized clinical trials, though this benefit comes with a modest, generally nonsignificant increase in major bleeding risk.⁴

Among the available direct oral anticoagulants, apixaban has shown a notably favorable safety profile specifically regarding gastrointestinal bleeding, distinguishing it somewhat from other medications in this class that have shown increased bleeding risk in this specific area.⁵

Prevention

For people with confirmed inherited thrombophilia, awareness of personal risk allows for more proactive prevention strategies during recognized high risk situations, including surgery, pregnancy, and prolonged immobility.

In cancer patients specifically, incorporating both traditional clinical risk factors and emerging genetic risk markers may eventually allow for more individually tailored thrombosis prevention strategies, though this approach remains an active area of ongoing research.²

Selecting appropriate anticoagulant therapy based on individual bleeding risk, including consideration of gastrointestinal bleeding risk when choosing among direct oral anticoagulants, supports safer, more personalized thrombosis prevention and treatment.⁵

Why Visual Communication Matters for Venous and Arterial Thrombosis

Explaining how inherited genetic variants and, in cancer patients, tumor specific mutations both contribute to clotting risk requires visuals that make these layered genetic contributions understandable to patients and clinical teams alike.

Pharmaceutical companies, hematology and oncology practices, and patient education organizations rely on clear illustration and animation to explain thrombosis genetics and support informed treatment decisions.

• Illustrating inherited thrombophilia mechanisms including factor V Leiden
• Animating how tumor specific mutations influence cancer associated thrombosis risk
• Explaining the mechanism of action of direct oral anticoagulants versus heparin
• Visualizing bleeding risk differences among anticoagulant treatment options
• Supporting patient education on thrombophilia testing and genetic counseling
• Creating training materials for hematology and oncology clinicians

How Biotic Artlab Supports Thrombosis Communication

We work with pharmaceutical companies, hematology and oncology practices, and patient advocacy organizations to create accurate, detailed visuals that make thrombosis genetics and treatment easier to understand.

• Custom 3D animations of inherited thrombophilia mechanisms
• Detailed illustrations of cancer associated thrombosis risk factors
• Mechanism of action animations comparing anticoagulant treatment options
• Patient facing materials on thrombophilia testing and genetic counseling
• Clinical training content for hematology and oncology teams
• Conference presentations and marketing visuals for thrombosis focused audiences

Frequently Asked Questions

What is thrombophilia?

Thrombophilia refers to an inherited or acquired tendency toward abnormal blood clotting, including specific genetic variants such as factor V Leiden.¹

Why is cancer associated with higher clotting risk?

Cancer diagnosis itself raises clotting risk, and this risk is further influenced by both inherited genetic thrombophilia and tumor specific genetic mutations.²

How common are protein C, protein S, and antithrombin deficiencies?

These inherited deficiencies together affect less than one to two percent of the general population, making them considerably less common than factor V Leiden.¹

What is the preferred treatment for cancer associated thrombosis?

Current guidelines recommend either low molecular weight heparin or direct oral anticoagulants as first line treatment options.⁴

Are direct oral anticoagulants safer than heparin?

They show lower recurrence rates but a modest increase in bleeding risk, with apixaban specifically showing a favorable gastrointestinal bleeding profile compared to some alternatives.⁵

Who should be tested for inherited thrombophilia?

Testing is generally considered for people with a personal or family history of blood clots, particularly at a young age or without an obvious cause, guided by professional society recommendations.³

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to thrombosis or hematologic oncology, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Factor V Leiden Thrombophilia.
2. National Center for Biotechnology Information. The Role of Germline and Somatic Mutations in Predicting Cancer Associated Thrombosis.
3. National Center for Biotechnology Information. Thrombophilia Testing, A British Society for Haematology Guideline.
4. National Center for Biotechnology Information. Direct Oral Anticoagulant Versus Low Molecular Weight Heparin for the Treatment of Cancer Associated Venous Thromboembolism.
5. National Center for Biotechnology Information. Efficacy and Safety of Apixaban Versus Dalteparin as a Treatment for Cancer Associated Venous Thromboembolism.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.